Patents by Inventor Laure Dumoutier

Laure Dumoutier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof
    Publication number: 20040110189
    Abstract: The invention involves isolation of nucleic acid molecules, the expression of which are upregulated by interleukin-9. The amino acid sequences of the proteins which correspond to the nucleic acid molecules show some structural features of cytokines. In addition to the nucleic acid molecules and the proteins, various uses of the molecules are disclosed. The molecules are referred to as T cell inducible factors.
    Type: Application
    Filed: July 25, 2003
    Publication date: June 10, 2004
    Inventors: Laure Dumoutier, Jamila Louahed, Jean-Christophe Renauld
  • Crystal structure of interleukin-22 and uses thereof
    Publication number: 20040002586
    Abstract: This invention provides the three dimensional structure of human IL-22 and recombinant human IL-22 with mutations in the receptor binding regions and the dimerization interface and nucleic acid molecule encoding same. This invention also relates to methods of using pharmaceutical formulations and mimetics of the recombinant IL-22 and to methods for generating mutants based on the crystalline structure of IL-22.
    Type: Application
    Filed: September 10, 2002
    Publication date: January 1, 2004
    Inventors: Ronaldo A.P. Nagem, Igor Polikarpov, Jean Christophe Renauld, Didier Colau, Laure Dumoutier
  • Isolated cytokine receptor LICR-2
    Publication number: 20030158100
    Abstract: The invention relates to new members of the Class II cytokine receptor family, such as LICR-2. The new member binds to AK155, and mediates STAT activation.
    Type: Application
    Filed: December 21, 2001
    Publication date: August 21, 2003
    Inventors: Jean-Christophe Renauld, Helmut Fickenscher, Laure Dumoutier, Simon Hor
  • Novel class II cytokine receptors and uses thereof
    Publication number: 20030023033
    Abstract: A new class II cytokine receptor has been identified, which comprises an interleukin-22 receptor molecule, and an interleukin-20 receptor &bgr; molecule. The complex binds to cytokines homologous to IL-10, including mda-7 and IL-20. Also described are methods for inhibiting effect of interleukin-22 and/or interleukin-20 on cells. The latter is especially useful in treatment of, e.g., skin diseases such as psoriasis.
    Type: Application
    Filed: July 26, 2001
    Publication date: January 30, 2003
    Inventors: Laure Dumoutier, Jean-Christophe Renauld
  • Method for influencing kinase pathways with IL-22
    Publication number: 20030012788
    Abstract: Interleukin-22 interacts with its receptor, referred to as IL-22R, and instigates a series of reactions, leading to activation of various molecules, such as JAK-1, Tyk2, and others. One can identify molecules which mediate this interaction by measuring the activity of one or more of the molecules in the pathway, to identify agonists and antagonists. These, in turn, are useful therapeutic agents, where inappropriate expression of one of the activated molecules is at issue, and requires amelioration.
    Type: Application
    Filed: July 26, 2002
    Publication date: January 16, 2003
    Inventors: Jean-Christophe Renauld, Diane Lejeune, Laure Dumoutier
  • Crystal structure of human interleukin-22
    Publication number: 20020187512
    Abstract: This invention provides the three dimensional structure of human IL-22 and recombinant human IL-22 with mutations in the receptor binding regions and the dimerization interface and nucleic acid molecule encoding same. This invention also relates to methods of using pharmaceutical formulations and mimetics of the recombinant IL-22 and to methods for generating mutants based on the crystalline structure of IL-22.
    Type: Application
    Filed: January 18, 2002
    Publication date: December 12, 2002
    Inventors: Ronaldo Alves Pinto Nagem, Igor Polikarpov, Jean Christophe Renauld, Didier Colau, Laure Dumoutier
  • Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses therefor
    Patent number: 6359117
    Abstract: The invention involves isolation of nucleic acid molecules, the expression of which are upregulated by interleukin-9. The amino acid sequences of the proteins which correspond to the nucleic acid molecules show some structural features of cytokines. In addition to the nucleic acid molecules and the proteins, various uses of the molecules are disclosed. The molecules are referred to as T cell inducible factors.
    Type: Grant
    Filed: July 16, 1999
    Date of Patent: March 19, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Laure Dumoutier, Jamila Louhed, Jean-Christophe Renauld
  • Isolated nucleic acid molecules which encode T cell inducible factors (TIFS), the proteins encoded, and uses thereof
    Patent number: 6331613
    Abstract: The invention involves isolation of nucleic acid molecules, the expression of which are upregulated by interleukin-9. The amino acid sequences of the proteins which correspond to the nucleic acid molecules show some structural features of cytokines. In addition to the nucleic acid molecules and the proteins, various uses of the molecules are disclosed. The molecules are referred to as T cell inducible factors.
    Type: Grant
    Filed: October 18, 1999
    Date of Patent: December 18, 2001
    Assignee: Ludwig Institue for Cancer Research
    Inventors: Laure Dumoutier, Jamila Louhed, Jean-Christophe Renauld
  • Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and used thereof
    Publication number: 20010024652
    Abstract: The invention involves isolation of nucleic acid molecules, the expression of which are upregulated by interleukin-9. The amino acid sequences of the proteins which correspond to the nucleic acid molecules show some structural features of cytokines. In addition to the nucleic acid molecules and the proteins, various uses of the molecules are disclosed. The molecules are referred to as T cell inducible factors.
    Type: Application
    Filed: December 29, 2000
    Publication date: September 27, 2001
    Inventors: Laure Dumoutier, Jamila Louahed, Jean-Christophe Renauld
  • Antibodies which specifically bind T Cell inducible factors (TIFs)
    Patent number: 6274710
    Abstract: The invention involves isolation of nucleic acid molecules, the expression of which are upregulated by interleukin-9. The amino acid sequences of the proteins which correspond to the nucleic acid molecules show some structural features of cytokines. In addition to the nucleic acid molecules and the proteins, various uses of the molecules are disclosed. The molecules are referred to as T cell induceable factors.
    Type: Grant
    Filed: October 26, 1998
    Date of Patent: August 14, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Laure Dumoutier, Jamila Louhed, Jean-Christophe Renauld